Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling
Year: 2006
Type: article
Abstract: The antitumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations. Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma-associated herpesvirus (KSHV). We find that (1) rapamycin is efficacious against PEL in culture and in a murine xenograft model; (2) mTOR, its activator Akt, and its target p70S6 kinase are phosphorylated in PEL; (3) rapamycin inhibits mTOR signaling as determined by S6 phosphorylation; (4) KSHV transcription is unaffected; (5) inhibition of IL-10 signaling correlates with drug sensitivity; and (6) addition of exogenous IL-10 or IL-6 can reverse the rapamycin growth arrest. This validates sirolimus as a new treatment option for PEL.
Source: Blood
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G1465922187, G164741270, G1815638046, Viral Infection and Primary Pulmonary Hypertension, G2579308029, G3879490787, Role of CX3CR1 in the anti-tumor effects of NK cells, G4150258224, G5398899240, G5414952080, G605456412, Role of KSHV Viral Proteins in Signaling and Pathogenesis, G7699855597, Southeast Regional Centers of Excellence for Biodefense & Emerging Infectious Di, G9000158818, G9000162070, G9000253134, ART Modulation of Viral Pathogenesis
OpenAlex ID: W2099904968
